Epigenetic frontier Volition is advancing epigenetic diagnostics with a focus on early detection and monitoring of cancer, sepsis, and related diseases through Nu.Q technology. Sales opportunities exist in expanding adoption of liquid biopsy and blood-based tests across human and veterinary medicine, leveraging current clinical trial momentum.

Commercialization momentum Recent press and clinical data highlighting prognostic value in lung cancer and progress toward commercialization of Nu.Q NETs suggest readiness for scaled partnerships, licensing discussions, and co-development deals with diagnostics manufacturers and clinical labs.

Strategic partnerships Volition has active collaboration with Sysmex to optimize Nu.Q NETs on their platform, signaling a viable path for channel partners and OEM licensing to accelerate market access and distribution in global diagnostics markets.

Diversified TAM Multiple pillars (Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer) and Capture-PCR positioning create a diversified total addressable market including veterinary oncology, human cancer, sepsis, and outbreak triage, presenting cross-selling and multi-portfolio upsell opportunities.

Funding and scale With significant capital raised and ongoing public offering activity, Volition is financially positioned to invest in expanded clinical programs, manufacturing scale, and international expansion to support rapid sales cycles and broader market penetration.